American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

REGENXBIO Inc. (RGNX)

$6.68 -6.83% NASDAQ: RGNX · 15-min delayed

ROCKVILLE, Maryland
Public · NASDAQ: RGNX
371 employees

Visit website Follow

$622.9MMarket cap

$170.4MRevenue · FY2025

-$193.9MNet income

371Employees

RGNXNASDAQ

2015IPO

About REGENXBIO Inc.

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: RGNX
Employees: 371
IPO date: Sep 17, 2015
Headquarters: 9804 MEDICAL CENTER DRIVE
ROCKVILLE, Maryland 20850
Phone: 240-552-8181
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 549300EOES47LATSET33

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: RGNX Nasdaq
SEC CIK: 1590877
LEI: 549300EOES47LATSET33
EIN: 471851754
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show REGENXBIO Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/regenxbio-inc/"><img src="https://americancompanies.com/badge/regenxbio-inc.svg" alt="REGENXBIO Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow REGENXBIO Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $170.4M
Net income: -$193.9M
Total assets: $453.0M
Market cap: $622.9M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: RGNX

$6.68 -6.83%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$5.65 $15.98

52-week range

Market cap: $622.9M
Shares outstanding: 93.3M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Sep 17, 2015

REGENXBIO Inc. (RGNX) Stock Price

Reported a net loss of $193.9M in FY2025.
Trading 58% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review REGENXBIO Inc..

Write a review

Newsroom

News about REGENXBIO Inc.

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm GlobeNewswire Inc. · 2026-07-13 · negative Diabetic Retinopathy Pipeline Insight 2026: Comprehensive Analysis of 50+ Companies and 55+ Drugs in Development GlobeNewswire Inc. · 2026-07-03 · neutral Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape GlobeNewswire Inc. · 2026-06-18 · positive REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX Benzinga · 2026-04-15 · negative INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX GlobeNewswire Inc. · 2026-04-14 · negative INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AMC Entertainment Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMC; APE GlobeNewswire Inc. · 2026-04-14 · negative

News & sentiment via Polygon.io

FAQ

REGENXBIO Inc.: frequently asked questions

Is REGENXBIO Inc. an American company?

REGENXBIO Inc. is a US-based company headquartered in Rockville, Maryland, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is REGENXBIO Inc. headquartered?

REGENXBIO Inc. is headquartered in Rockville, Maryland, United States.

Is REGENXBIO Inc. publicly traded?

Yes — REGENXBIO Inc. is a publicly traded company. Its stock trades under the ticker symbol RGNX on the NASDAQ.

What does REGENXBIO Inc. do?

REGENXBIO Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore